• OTS
  • August 31, 2019
SHARE
Post Views: 566

Echigoya Y, Lim KRQ, Melo D, Bao B, Trieu N, Mizobe Y, Maruyama R, Mamchaoui K, Tanihata J, Aoki Y, Takeda S, Mouly V, Duddy W, Yokota T.
Mol Ther. 2019 Jul 26. pii: S1525-0016(19)30325-9.

PubMed

Related articles

A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome

A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome

April 23rd, 2021
Perspectives on the Designation of Oligonucleotide Starting Materials

Perspectives on the Designation of Oligonucleotide Starting Materials

March 15th, 2021
Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

March 15th, 2021
Splicing-associated chromatin signatures: a combinatorial and position-dependent role for histone marks in splicing definition

Splicing-associated chromatin signatures: a combinatorial and position-dependent role for histone marks in splicing definition

February 16th, 2021
The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

February 16th, 2021
In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice

In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice

February 16th, 2021